General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
3 Gene Editing Stocks That Could Make Your Grandchildren Rich | news.google.com • |
3 Gene Editing Stocks That Could Make Your Grandchildren Rich | investorplace.com • |
If You Had Bought Editas Medicine (NASDAQ:EDIT) Stock Three Years Ago, You Could Pocket A 65% Gain Today | news.google.com • |
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-07 | 2024-06 | -0.69 | N/A | N/A | N/A |
2024-05-08 | 2024-03 | -0.63 | -0.76 | -0.13 | -20.63% |
2024-02-28 | 2023-12 | -0.52 | -0.23 | 0.29 | 55.77% |
2023-11-03 | 2023-09 | -0.64 | -0.55 | 0.09 | 14.06% |
2023-08-02 | 2023-06 | -0.76 | -0.56 | 0.2 | 26.32% |
2023-05-05 | 2023-03 | -0.79 | -0.71 | 0.08 | 10.13% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-17 | JP Morgan | Upgrade | Underweight | Neutral |
2023-10-16 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-09-28 | Stifel | Upgrade | Hold | Buy |
2023-09-12 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-02 | Oppenheimer | Upgrade | Perform | Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-29 | BURKLY LINDA | Officer | 85.02K | Stock Award(Grant) |
2023-12-04 | EATON BRUCE E | Chairman of the Board | 74.79K | Sale |
2024-05-12 | HOPFIELD JESSICA | Director | 67.70K | Purchase |
2024-05-19 | LUCERA ERICK J. | Chief Financial Officer | 116.83K | Sale |
2024-06-03 | MEI BAISONG | Officer | 141.03K | Sale |
2021-12-21 | MICHAELS LISA ANNE | Officer | 22.68K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 8.17M | 67.20M | 10.00% |
2023-06-29 | Blackrock Inc. | 7.60M | 62.51M | 9.30% |
2023-06-29 | State Street Corporation | 6.64M | 54.66M | 8.14% |
2023-06-29 | Deep Track Capital, Lp | 3.45M | 28.42M | 4.23% |
2023-06-29 | Avidity Partners Management, LP | 3.00M | 24.69M | 3.68% |
2023-06-29 | Marshall Wace LLP | 2.84M | 23.36M | 3.48% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 4.85M | 43.18M | 5.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.49M | 20.51M | 3.05% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.10M | 17.25M | 2.57% |
2023-08-30 | iShares Russell 2000 ETF | 1.60M | 14.28M | 1.96% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.16M | 9.57M | 1.42% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.01M | 8.32M | 1.24% |
Very nice
Trying to time stocks on a daily, weekly even monthly basis bears no interest to my style. Stocks run up and attract sellers. Sellers have to accept lower prices due to imbalance. Lower prices attract new buyers who did not want to chase the stock up. Stock rises again and cycle repeats. As long as nothing has changed fundamentally you need not worry. Stay diversified in a minimum of 5 good companies and watch them as a whole. Watching individual moves will keep you on an emotional roller coaster. Not good for investing long term.
Want to add here too
It’s all part of a healthy rise. Back and fill back and fill
EDIT will prevail.
The no question thing was very odd. Especially considering the fact that 16 different analysts cover the stock. Just goes to show that Cathie Woods might be correct in saying that most are intimidated by the investment due to lack of understanding. How is a series seven certificate holder going to question a Biochemist with a PHD. Kind of makes sense.
Facts Bill and Google put millions way back when. Hold tight thing could have a 15bil market cap in next 18mo with good results on Brilliance
Eddie Murphy Trading Places for all my old heads. I CAN SEE I CAN SEE ITS A MIRACLE.
Nice move Pre market indeed. Hopefully good news coming sooner then later
More news is coming soon imho it has been more then enough time for results. If it was not working there would have been no continuance of injecting more people. Also Brown would not be as bullish as he is. Be patient I believe it will pay off.
$OBSV Analysts expect $16-$36 per share.
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year
There are two markets Dow and Nasdaq. The leaders of Tech are back in a bull market. 5G is alive and kicking. There is money to be made in any market. My advice to anyone is to stay invested with 20-30 percent in cash.
Exactly......their going to clear you to keep poking someone in the eye with no results. Just a matter of time before this explodes without warning
Agreed agreed agreed
CC was basically a summation of the press release verbatim. They seemed optimistic regarding LCA 10 and Sickle Cell going forward. No questions came from audience.
Listened
Interesting option trading too 516 contracts on the May 45
Nope. Think the cats out the bag. Tomorrow will be very interesting to say the least. Blessings to all
100 is just the first stop 200 is in 3mo over the next 12mo 400 plus isn’t off the table.
I agree if they were not making progress with LCA10 they would not announce moving on to tumors. Any day folks any day.